PCSK9 as predictor for recurrent cardiovascular disease in familial hypercholesterolemia

被引：2
作者：
Reeskamp, Laurens F. [1 ]
Tromp, Tycho R. [1 ]
Hovingh, G. Kees [1 ]
机构：
[1] Univ Amsterdam, Amsterdam UMC, Dept Vasc Med, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands
来源：
EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY | 2021年 / 28卷 / 03期
关键词：
CALCIFICATION; STATINS; EVENTS; RISK;
D O I：
10.1177/2047487319886140
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：270 / 271
页数：2
相关论文
共 50 条
  • [31] PCSK9 Inhibitors as Adjunctive Therapies in Hypercholesterolemia: Benefits, Limitations, and Possible Alternatives
    Hamad, Mawieh
    Muhammad, Jibran Sualeh
    Rah, Bilal
    Hasan, Haydar
    Taneera, Jalal
    Soofi, Abdulsalam
    Awadallah, Samir
    ADVANCED THERAPEUTICS, 2023, 6 (09)
  • [32] PCSK9 Inhibition to Reduce Cardiovascular Risk Tempering Expectations
    Waters, David D.
    Hsue, Priscilla Y.
    CIRCULATION RESEARCH, 2017, 120 (10) : 1537 - 1539
  • [33] Exploration of PCSK9 as a Cardiovascular Risk Factor Is There a Link to the Platelet?
    Gurbel, Paul A.
    Navarese, Eliano P.
    Tantry, Udaya S.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2017, 70 (12) : 1463 - 1466
  • [34] Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial Hypercholesterolemia: A Systematic Review and Meta-Analysis
    Xiao, Guoguang
    Gao, Shan
    Xie, Yongmei
    Wang, Zhiling
    Shu, Min
    MEDICINA-LITHUANIA, 2024, 60 (10):
  • [35] Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors. A new drug class for the treatment of hypercholesterolemia
    Martinez de Victoria, Emilio Ortega
    ENDOCRINOLOGIA DIABETES Y NUTRICION, 2017, 64 (07): : 341 - 344
  • [36] Lipids and PCSK9 inhibition in chronic kidney disease
    Schunk, S. J.
    Fliser, D.
    Speer, T.
    NEPHROLOGE, 2020, 15 (05): : 285 - 292
  • [37] Understanding PCSK9 and anti-PCSK9 therapies
    McKenney, James M.
    JOURNAL OF CLINICAL LIPIDOLOGY, 2015, 9 (02) : 170 - 186
  • [38] High burden of recurrent cardiovascular events in heterozygous familial hypercholesterolemia: The French Familial Hypercholesterolemia Registry OCR
    Beliard, Sophie
    Boccara, Franck
    Cariou, Bertrand
    Carrie, Alain
    Collet, Xavier
    Farnier, Michel
    Ferrieres, Jean
    Krempf, Michael
    Peretti, Noel
    Rabes, Jean-Pierre
    Varret, Mathilde
    Vimont, Alexandre
    Charriere, Sybil
    Bruckert, Eric
    ATHEROSCLEROSIS, 2018, 277 : 334 - 340
  • [39] Plasma kinetics of mature PCSK9, furin-cleaved PCSK9, and Lp(a) with or without administration of PCSK9 inhibitors in acute myocardial infarction
    Nakamura, Akihiro
    Kanazawa, Masanori
    Kagaya, Yuta
    Kondo, Masateru
    Sato, Kenjiro
    Endo, Hideaki
    Nozaki, Eiji
    JOURNAL OF CARDIOLOGY, 2020, 76 (04) : 395 - 401
  • [40] Impact of PCSK9 mutations on incidences of hypercholesterolemia: A meta-analysis to infer correlation
    Singhal, Monisha
    Agrawal, Raadhika
    Gupta, Nidhi
    META GENE, 2022, 31
12345